Limits of tumour treatment follow up by surface coil 31P magnetic resonance spectroscopy. The case of sarcosinamide-CNU treated ependymoblastoma.

Abstract

Ependymoblastoma tumour bearing mice were treated with sarcosinamide-CNU and compared with untreated mice with regard to tumour growth, pathological examinations and levels of phosphorylated metabolites measured by in vivo nuclear magnetic resonance spectroscopy. The response to the drug was demonstrated by its effect on tumour growth and with pathological examinations. Spectra evolution was different from controls for only four treated tumours out of eight.

• Authors: L Le Moyec, E Le Rumeur, F Darcel, M Chatel, J D de Certaines, C Remy, A François, S Lotito, A L Benabib
• Journal: NMR in biomedicine (NMR Biomed) Vol. 2 Issue 1 Pg. 34-8 (Jun 1989) ISSN: 0952-3480 [Print] England
• PMID: 2484278 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 1-(2-chloroethyl)-1-nitrosourea
• N-methylglycinamide
• Ethylnitrosourea
• Sarcosine

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Ependymoma (drug therapy)
• Ethylnitrosourea (administration & dosage)
• Follow-Up Studies
• Magnetic Resonance Spectroscopy
• Mice
• Sarcosine (administration & dosage, analogs & derivatives)